Unknown

Dataset Information

0

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.


ABSTRACT: We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan.A total of 373 subjects were randomized to receive placebo (n=126), istradefylline 20 mg/day (n=123), or istradefylline 40 mg/day (n=124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (-0.99 hours, P=.003) and istradefylline 40 mg/day (-0.96 hours, P=.003) groups compared with the placebo group (-0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment.

SUBMITTER: Mizuno Y 

PROVIDER: S-EPMC3842830 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.

Mizuno Yoshikuni Y   Kondo Tomoyoshi T  

Movement disorders : official journal of the Movement Disorder Society 20130311 8


<h4>Background</h4>We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan.<h4>Methods</h4>A total of 373 subjects were randomized to receive placebo (n=126), istradefylline 20 mg/day (n=123), or istradefylline 40 mg/day (n=124). The primary efficacy variable was the change in daily OFF time. Other s  ...[more]

Similar Datasets

| S-EPMC8609697 | biostudies-literature
| S-EPMC7367999 | biostudies-literature
| S-EPMC3292742 | biostudies-literature
| S-EPMC6635589 | biostudies-literature
| S-EPMC6383678 | biostudies-literature
| S-EPMC5965927 | biostudies-literature
| S-EPMC6202948 | biostudies-literature
| S-EPMC4186821 | biostudies-literature
| S-EPMC6772554 | biostudies-literature
| S-EPMC3008651 | biostudies-literature